ONTARGET®, TRANSCEND® and PRoFESS™: the latest findings and opinions
October 2008
Despite advances in the management of cardiovascular risk factors, cardiovascular disease (CVD) remains one of the leading causes of morbidity and mortality worldwide – and continues to increase in prevalence, particularly in the developing world. New evidence that raises new potentials and discussions in the prevention and management of CVD is therefore of great interest.
2008 saw the completion and publication of the ONTARGET®, TRANSCEND® and PRoFESS™ trials. Collectively with cardiovascular (CV) outcome data from over 50,000 patients, these studies provide a valuable opportunity to examine current practice and therapeutic options in protecting against CVD.
During Oct 2008, a symposium supported by Bayer Schering Pharma was conducted in Athens, Greece, where members of the ICMA faculty presented the most recent evidence and clinical opinions concerning the outcomes of ONTARGET®, TRANSCEND® and PRoFESS™. The symposium, chaired by Dr. Alejandro de la Sierra, examined the trials’ results and the clinical issues surrounding morbi-mortality trials, new evidence and guidelines in clinical practice.
The full symposium can be viewed online by clicking on the links below:
Additional information on the trials’ rationale, design and results can be found by accessing the links below:
